{"entity":{"id":"nct05302284","kind":"trial","name":"A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma","aka":[],"tldr":"A phase 3 trial of Toripalimab, Gemcitabine, Cisplatin and Carboplatin in bladder & urothelial cancer, run by RemeGen Co., Ltd., now recruiting.","summary":"A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma is a phase 3 interventional study registered as NCT05302284 by RemeGen Co., Ltd., with 452 participants planned, started 2022-06-14 and due to reach its primary completion in 2026-12-31. Interventions recorded: RC48-ADC, Toripalimab, Gemcitabine, Cisplatin and Carboplatin.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05302284","url":"https://clinicaltrials.gov/study/NCT05302284"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial","muscle-invasive-bladder-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["toripalimab","gemcitabine","cisplatin","carboplatin"],"companies":["remegen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05302284","phase":"3","setting":"A Open-Label, Multicenter, Randomised, Controlled Phase 3 Study of RC48-ADC Plus Toripalimab Versus Chemotherapy Alone in Previously Untreated Unresectable Locally Advanced or Metastatic Urothelial Carcinoma With HER2-Expressing","sponsor":"RemeGen Co., Ltd.","started":"2022-06-14","startedType":"actual","enrolled":452,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05302284/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"remegen","kind":"company","name":"RemeGen","route":"/companies/remegen/"}]}}